Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Protein Design Labs (PDLI): Stock strong -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (208)	5/22/2002 1:26:35 AM
From: tuck	Respond to of 407

PDLI takes a swing at another indication, but placebo throws a curve . . . >>SAN FRANCISCO -(Dow Jones)- Protein Design Labs (NasdaqNM: PDLI - News) Inc. (PSLI) said preliminary Phase I/II clinical results of its Smart Anti-Gamma Interferon antibody in Crohn's disease showed a reduction in the Crohn's Disease Activity Index, or CDAI, score. Crohn's disease is a form of inflammatory bowel disease. In a press release Tuesday, the company said the study of 42 patients showed that the antibody was "well tolerated" and all reported adverse events were mild to moderate. Under stage A of the trial, Protein Design reported that 50% of the patients responded and none achieved remission at the lowest dose of the antibody, while 71% of patients responded and 50% achieved remission at the highest dose tested. In the placebo group, 60% of the patients responded and 40% achieved a remission. Of the 18 patients that entered into stage B of the trial, 11 of the 13 patients who received the antibody maintained a CDAI score at study day 113 that was at least 70 points below their baseline score. These patients received either three additional doses of the drug or placebo at four-week intervals. A total of three of the four patients who received the placebo maintained their response at study day 113. The company said a multicenter Phase II clinical trial is currently underway to address the unusually high placebo rates in comparison to historic rates in other Crohn's disease trials and to obtain a "clearer" picture of the potential efficacy of the antibody.<< snip Cheers, Tuck